Article Text

Download PDFPDF
Clear Cell Carcinoma of the Endometrium: Evaluation of Prognostic Parameters in a Multi-institutional Cohort of 165 Cases
  1. Eman Abdulfatah, MD*,
  2. Sharif Sakr, MD*,
  3. Sumi Thomas, MD,
  4. Zaid Al-Wahab, MD*,
  5. David G. Mutch, MD,
  6. Sean Dowdy, MD,
  7. Sudeshna Bandyopadhyay, MD*,
  8. Adnan Munkarah, MD§,
  9. Mohamed Elshaikh, MD,
  10. Robert Morris, MD and
  11. Rouba Ali-Fehmi, MD*
  1. *Department of Pathology, Wayne State University, Detroit, MI;
  2. Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN;
  3. Department of Obstetrics and Gynecology, Washington University, St Louis, MO; and Departments of
  4. §Obstetrics and Gynecology and
  5. Radiation Oncology, Henry Ford Hospital/Wayne State University; and
  6. Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI.
  1. Address correspondence and reprint requests to Eman Abdulfatah, MD, Department of Pathology, Wayne State University, 540 E Canfield Ave, Detroit, MI 48201. E-mail: eabdulfa@med.wayne.edu; Eman.abdulfatah@gmail.com.

Abstract

Objectives Clear cell carcinoma (CCC) comprises a rare yet an aggressive subtype, accounting for less than 5% of all uterine carcinomas. Several clinicopathologic features have been predictive of poor prognosis; however, data remain controversial. The aim of this study was to evaluate the clinicopathologic features of a multi-institutional cohort of endometrial CCC in order to identify which, if any, have prognostic significance.

Methods Retrospective review of endometrial CCC diagnosed between 1995 and 2012 at 3 institutions was conducted to evaluate clinicopathologic parameters: age, race, tumor size, stage, myometrial invasion (MI), lymphovascular invasion, lymph node and adnexal involvement, adjuvant therapy, and outcomes. Data were analyzed using Fisher exact, Cox regression, and Kaplan-Meier analyses.

Results Patients’ ages ranged from 36 to 90 years (median, 67 years). The median tumor size was 3.6 cm. Inner-half MI was present in 44%, lymphovascular invasion in 34%, adnexal involvement in 16%, and lymph node metastasis in 30% of cases. Fifty-eight percent of the patients presented with early-stage disease. The 5-year overall survival (OS) was 58%. Shorter disease-free interval (DFI) was significantly associated with older age at diagnosis (>70 years), advanced-stage disease, adnexal involvement, and deep MI (P = 0.005, P = 0.001, P = 0.001, and P = 0.003, respectively). Patients who received adjuvant chemotherapy had a significantly worse DFI and 5-year OS (P = 0.001 and P = 0.001, respectively). A significantly shorter 5-year OS was noted with advanced stage (III–IV) and presence of adnexal involvement (P = 0.001 and P = 0.021, respectively). On Cox regression analysis, advanced-stage disease, older age, and adnexal involvement were significant independent predictors of worse DFI (P = 0.001, P = 0.005, and P = 0.019, respectively), whereas inner-half MI was a significant independent predictor of longer DFI (P = 0.004). Adjuvant radiotherapy alone was a significant independent predictor of better 5-year OS (P = 0.012).

Conclusions In our series of endometrial CCC, older age at diagnosis, advanced stage, deep MI, and adnexal involvement were independent poor prognostic factors. Adjuvant radiotherapy had a significant positive impact on 5-year OS.

  • Clear cell carcinoma
  • Clinicopathologic
  • Prognostic
  • Radiotherapy

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.